Key Highlights
- Omeros (NASDAQ:OMER) fell about 10.4% after hours on November 16, 2026 after reporting third-quarter YARTEMLEA net Revenue of USD 35.9 million, up 26% from the second quarter.
- A USD 62.0 million non-cash loss on the Fair Value of its 2029 notes produced a GAAP net loss of USD 57.4 million, or USD 0.79 per share.
- On an adjusted basis, Omeros earned USD 4.7 million, or USD 0.06 per share, and generated USD 13.3 million of operating cash flow.
- In the same after-hours session, Insight Molecular Diagnostics (IMDX) fell about 18.8% after announcing an underwritten public stock offering.
Growth That Fell Short of Hopes
Omeros (NASDAQ:OMER) is in the early commercial phase of YARTEMLEA, its narsoplimab treatment for transplant-associated thrombotic microangiopathy, a rare and often fatal complication of stem-cell transplants. Third-quarter gross sales reached USD 41.8 million, up 30% from the second quarter, and net revenue rose 26% to USD 35.9 million. The gap between the two widened, with gross-to-net deductions rising to 14.0% from 11.5%, reflecting discounts and rebates as hospital coverage broadens. Sequential growth of this size would normally be welcome, but net revenue came in below what investors had expected, which is the most likely reason for the after-hours decline. Underlying profitability improved. Operating Income was USD 4.5 million, up from USD 0.1 million in the second quarter, and Operating Cash Flow was positive at USD 13.3 million. A new technology add-on payment from Medicare, effective October 1 and worth up to USD 287,079 per eligible inpatient case, should support hospital adoption in the fourth quarter and beyond.
The Accounting Loss and the Balance Sheet
The headline GAAP loss of USD 57.4 million, or USD 0.79 per share, was driven by a USD 62.0 million non-cash loss from marking to market the derivative embedded in the company's convertible notes due 2029. Because the conversion feature gains value when the share price rises, a stronger stock produces an accounting loss, which is why adjusted Net Income of USD 4.7 million, or USD 0.06 per share, gives a clearer view of operations. Omeros ended September with USD 95.3 million of cash and short-term investments. Earlier in the year it repurchased USD 30.5 million of principal on the 2029 notes for USD 60.2 million, leaving about USD 40.3 million outstanding and reducing potential conversion shares to 6.5 million from 11.4 million. The company also expects near-term milestone payments of up to USD 100 million from the sale of an earlier asset to a large drug maker, with more than USD 1.8 billion of further milestones eligible.
Regulatory Risks and the IMDX Offering
The main overhang for Omeros (NASDAQ:OMER) is Europe, where the medicines committee issued a negative opinion in October 2026 on the narsoplimab application after re-examining an earlier negative view. That limits the near-term market to the United States. Pipeline programs in cocaine use disorder, acute myeloid leukemia and lung injury are at early stages. Separately, Insight Molecular Diagnostics fell about 18.8% after hours after announcing an underwritten public offering of common stock, with a 30-day option for underwriters to buy up to 15% more. The company, which sells a blood test that detects organ transplant rejection, reported third-quarter revenue of USD 559,000 and ended the quarter with USD 11.8 million in cash, down from USD 18.7 million, so the raise addresses an urgent funding need at the cost of dilution. An FDA decision on its test kit is due before January 21, 2027.
Where Things Stand
Omeros grew YARTEMLEA sales 26% and generated positive operating cash flow, but revenue fell short of expectations and a non-cash charge produced a large GAAP loss. Medicare add-on payments and milestone income support the outlook, while Europe remains closed for now. IMDX's offering highlights the dilution risk facing cash-poor small caps.


_11_18_2026_14_40_45_405856.jpg)



Please wait processing your request...